FDA approves Ventana Medical's breast cancer test

06/15/2011 | Wall Street Journal, The

Ventana Medical Systems, a Roche Holding subsidiary, has received FDA approval for its Inform Dual ISH genetic test, which is designed to identify patients who are likely to benefit from Herceptin, Genentech's breast cancer drug. The test works by looking for the presence of the HER2 gene in patients' tumor samples.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
PacificSource
Bend, OR
Clinical Appeals RN
MJHS
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ